Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Moderate Buy” from Analysts

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $82.2308.

Several research firms recently issued reports on PTGX. Leerink Partners assumed coverage on shares of Protagonist Therapeutics in a research report on Friday, September 12th. They issued an “outperform” rating and a $73.00 price target for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. Wedbush boosted their target price on shares of Protagonist Therapeutics from $70.00 to $86.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 28th. JPMorgan Chase & Co. upped their target price on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Leerink Partnrs upgraded Protagonist Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $89.65 on Friday. The stock’s 50 day simple moving average is $78.77 and its 200 day simple moving average is $63.27. The company has a market cap of $5.60 billion, a P/E ratio of 144.60 and a beta of 2.19. Protagonist Therapeutics has a fifty-two week low of $33.70 and a fifty-two week high of $93.25.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. The firm had revenue of $4.71 million during the quarter, compared to analyst estimates of $5.41 million. Equities analysts predict that Protagonist Therapeutics will post 2.43 earnings per share for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $81.62, for a total transaction of $979,440.00. Following the transaction, the director owned 5,130 shares of the company’s stock, valued at $418,710.60. The trade was a 70.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

Several large investors have recently bought and sold shares of PTGX. FNY Investment Advisers LLC bought a new position in shares of Protagonist Therapeutics during the second quarter valued at about $27,000. Bessemer Group Inc. increased its stake in Protagonist Therapeutics by 171.0% in the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after buying an additional 318 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of Protagonist Therapeutics during the 3rd quarter worth approximately $29,000. CWM LLC boosted its stake in shares of Protagonist Therapeutics by 201.5% in the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after buying an additional 407 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.